Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRINASDAQ:HEPANASDAQ:ONVONASDAQ:SPRC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRIGRI Bio$1.31-0.8%$1.50$1.10▼$59.33$2.83M-1.68108,778 shs94,895 shsHEPAHepion Pharmaceuticals$0.07-7.8%$0.17$0.04▼$56.00$806K1.581.31 million shs1,333 shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shsSPRCSciSparc$0.30+1.4%$0.31$0.20▼$1.79$3.32M0.724.16 million shs91,637 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRIGRI Bio0.00%+1.54%+10.00%-83.62%-97.08%HEPAHepion Pharmaceuticals0.00%+14.12%+4.44%-89.22%-99.84%ONVOOrganovo0.00%0.00%0.00%-31.77%-78.97%SPRCSciSparc0.00%-7.79%-3.74%-8.67%-68.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRIGRI Bio1.9447 of 5 stars3.52.00.00.01.40.01.3HEPAHepion Pharmaceuticals0.6765 of 5 stars0.05.00.00.01.10.00.6ONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/ASPRCSciSparc0.4372 of 5 stars0.05.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRIGRI Bio 3.00Buy$22.001,579.39% UpsideHEPAHepion Pharmaceuticals 0.00N/AN/AN/AONVOOrganovo 0.00N/AN/AN/ASPRCSciSparc 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GRI, ONVO, HEPA, and SPRC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.004/14/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRIGRI BioN/AN/AN/AN/A$7.68 per shareN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/AONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00SPRCSciSparc$1.31M2.57N/AN/A$0.86 per share0.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRIGRI Bio-$8.21M-$11.56N/AN/AN/AN/A-275.15%-168.22%8/12/2025 (Estimated)HEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%8/11/2025 (Estimated)ONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/ASPRCSciSparc-$6.28MN/A0.00∞N/AN/AN/AN/AN/ALatest GRI, ONVO, HEPA, and SPRC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRIGRI BioN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRIGRI BioN/A1.411.41HEPAHepion PharmaceuticalsN/A1.301.30ONVOOrganovoN/A0.721.72SPRCSciSparcN/A5.365.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRIGRI Bio33.95%HEPAHepion Pharmaceuticals17.24%ONVOOrganovo8.23%SPRCSciSparc25.06%Insider OwnershipCompanyInsider OwnershipGRIGRI Bio0.13%HEPAHepion Pharmaceuticals0.06%ONVOOrganovo3.72%SPRCSciSparc1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRIGRI Bio12.14 million2.14 millionNot OptionableHEPAHepion Pharmaceuticals2010.93 million6.63 millionNo DataONVOOrganovo201.70 million14.79 millionOptionableSPRCSciSparc411.23 million11.06 millionNot OptionableGRI, ONVO, HEPA, and SPRC HeadlinesRecent News About These CompaniesSciSparc (NASDAQ:SPRC) Stock Price Down 0.8% - Here's What HappenedJune 21 at 2:15 AM | americanbankingnews.comSciSparc secures Japanese patent for pain relief comboMay 28, 2025 | investing.comSciSparc Unveils Japanese Patent for Novel Pain Relief CombinationMay 27, 2025 | tipranks.comSciSparc Ltd. Announces Publication of Novel Japanese Patent for Enhanced Pain Management Therapy Combining Paracetamol and PEAMay 27, 2025 | quiverquant.comSciSparc Announces Publication of Japanese Patent ApplicationMay 27, 2025 | globenewswire.comSciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc.May 13, 2025 | nasdaq.comSciSparc and Clearmind Secure European Patent for Cocaine Addiction TherapyMay 13, 2025 | tipranks.comSciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine AddictionMay 12, 2025 | uk.finance.yahoo.comSciSparc announces collaboration with Clearmind MedicineApril 26, 2025 | markets.businessinsider.comScisparc and Clearmind Push into Eating Disorder And Addiction Treatment With New PatentsApril 25, 2025 | theglobeandmail.comSciSparc and Clearmind File Patent for Eating Disorder TreatmentApril 25, 2025 | tipranks.comSciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating DisordersApril 25, 2025 | globenewswire.comSciSparc Extends Deadline for Miza III Ventures DealApril 1, 2025 | tipranks.comSciSparc Ltd. Extends Merger Agreement with AutoMax MotorsApril 1, 2025 | tipranks.comSciSparc files to sell 61.21M ordinary shares for holdersMarch 26, 2025 | markets.businessinsider.comSciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent ApplicationMarch 11, 2025 | tipranks.comClearmind Medicine Inc.: Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South KoreaMarch 10, 2025 | finanznachrichten.deSciSparc announces publication of patent via Clearmind collaborationMarch 10, 2025 | markets.businessinsider.comSciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine AddictionMarch 10, 2025 | quiverquant.comSciSparc Ltd. Agrees to Sell MitoCareX to N2OFFMarch 3, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Quality Stocks Trading Near 52-Week LowsBy Gabriel Osorio-Mazilli | May 30, 2025View 3 Quality Stocks Trading Near 52-Week LowsWhich U.S. Towns See Economic Change First? [2025 Survey]By MarketBeat Staff | June 9, 2025View Which U.S. Towns See Economic Change First? [2025 Survey]GRI, ONVO, HEPA, and SPRC Company DescriptionsGRI Bio NASDAQ:GRI$1.31 -0.01 (-0.76%) As of 04:00 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Hepion Pharmaceuticals NASDAQ:HEPA$0.07 -0.01 (-7.75%) As of 02:12 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.SciSparc NASDAQ:SPRC$0.30 +0.00 (+1.35%) Closing price 03:55 PM EasternExtended Trading$0.30 0.00 (0.00%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
